NF-kappa B signaling pathway is associated with metformin resistance in type 2 diabetes patients
Introduction Metformin is an essential medicine that is most widely prescribed frontline for the treatment of Type 2 diabetes (T2D). Metformin upgraded glycemic control in T2D patients without hypoglycemic effects in patients. This assessment aims to understand molecular mechanism mechanisms in non-...
Gespeichert in:
| Veröffentlicht in: | Journal of diabetes and metabolic disorders 2024-07, Vol.23 (2), p.2021-2030 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2030 |
|---|---|
| container_issue | 2 |
| container_start_page | 2021 |
| container_title | Journal of diabetes and metabolic disorders |
| container_volume | 23 |
| creator | Mansouri, Vahid Bandarian, Fatemeh Razi, Farideh Razzaghi, Zahra Rezaei-Tavirani, Majid Rezaei, Mitra Arjmand, Babak Rezaei-Tavirani, Mostafa |
| description | Introduction
Metformin is an essential medicine that is most widely prescribed frontline for the treatment of Type 2 diabetes (T2D). Metformin upgraded glycemic control in T2D patients without hypoglycemic effects in patients. This assessment aims to understand molecular mechanism mechanisms in non-responder patients to metformin.
Methods
Gene expression profiles of responder and non-responder T2D patients to metformin are extracted from Gene Expression Omnibus (GEO) and are evaluated by the GEO2R program to find the significant differentially expressed genes (DEGs). The significant DEGs have been studied via action map gene ontology analyses.
Results
Results indicate that 563 significant DEGs discriminate non-responders from responder groups. “NF-kappa B signaling pathway” and 11 DEGs including BIRC3, CCL4L2, CXCL2, ICAM1, LYN, MYD88, RELA, SYK, TLR4, TNFAIP3, and TRIM25 were pointed out as core of drug resistance.
Conclusion
It can be concluded that there are differences between gene expression analysis, the response of diabetic patients to metformin. Results indicate that dysregulation of the “NF-kappa B signaling pathway” and TNFAIP3, BIRC3, RELA, MYD88, TLR4, and ICAM1 is associated with drug resistance in T2D patients. |
| doi_str_mv | 10.1007/s40200-024-01458-8 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_3134068883</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A800331134</galeid><sourcerecordid>A800331134</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-9d926aa4f68265ea13bc8da3196e0399b1142c010e70313483f74e5756d90c4c3</originalsourceid><addsrcrecordid>eNp9kU1rFTEUhoMottT-ARcSEMTN1HzMZDLLWlorFN3oOuZmztybOpOMORnK_ffmOrW0ICaLfD3vC-Eh5DVnZ5yx9gPWTDBWMVFXjNeNrvQzcixEwyvVaP780f6InCLesjLaVmuuXpIj2SnOGt4ekx9frqqfdp4t_UjRb4MdfdjS2ebdnd1Tj9QiRudthp7e-byjE-QhpskHmgA9Zhsc0HLK-xmooL23G8iAhwoPIeMr8mKwI8Lp_XpCvl9dfru4rm6-fvp8cX5TOSlUrrq-E8raelBaqAYslxuneyt5p4DJrttwXgvHOIOWSS5rLYe2hqZtVN8xVzt5Qt6vvXOKvxbAbCaPDsbRBogLmkOIKa21LOjbFd3aEYwPQ8zJugNuzjVjUvLCFursH1SZPUzexQCDL_dPAu8eBXZgx7zDOC7Zx4BPQbGCLkXEBIOZk59s2hvOzEGuWeWaItf8kWt0Cb25_9-ymaB_iPxVWQC5AliewhaSuY1LKkLxf7W_AZyaq5c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3134068883</pqid></control><display><type>article</type><title>NF-kappa B signaling pathway is associated with metformin resistance in type 2 diabetes patients</title><source>Springer Nature - Complete Springer Journals</source><creator>Mansouri, Vahid ; Bandarian, Fatemeh ; Razi, Farideh ; Razzaghi, Zahra ; Rezaei-Tavirani, Majid ; Rezaei, Mitra ; Arjmand, Babak ; Rezaei-Tavirani, Mostafa</creator><creatorcontrib>Mansouri, Vahid ; Bandarian, Fatemeh ; Razi, Farideh ; Razzaghi, Zahra ; Rezaei-Tavirani, Majid ; Rezaei, Mitra ; Arjmand, Babak ; Rezaei-Tavirani, Mostafa</creatorcontrib><description>Introduction
Metformin is an essential medicine that is most widely prescribed frontline for the treatment of Type 2 diabetes (T2D). Metformin upgraded glycemic control in T2D patients without hypoglycemic effects in patients. This assessment aims to understand molecular mechanism mechanisms in non-responder patients to metformin.
Methods
Gene expression profiles of responder and non-responder T2D patients to metformin are extracted from Gene Expression Omnibus (GEO) and are evaluated by the GEO2R program to find the significant differentially expressed genes (DEGs). The significant DEGs have been studied via action map gene ontology analyses.
Results
Results indicate that 563 significant DEGs discriminate non-responders from responder groups. “NF-kappa B signaling pathway” and 11 DEGs including BIRC3, CCL4L2, CXCL2, ICAM1, LYN, MYD88, RELA, SYK, TLR4, TNFAIP3, and TRIM25 were pointed out as core of drug resistance.
Conclusion
It can be concluded that there are differences between gene expression analysis, the response of diabetic patients to metformin. Results indicate that dysregulation of the “NF-kappa B signaling pathway” and TNFAIP3, BIRC3, RELA, MYD88, TLR4, and ICAM1 is associated with drug resistance in T2D patients.</description><identifier>ISSN: 2251-6581</identifier><identifier>EISSN: 2251-6581</identifier><identifier>DOI: 10.1007/s40200-024-01458-8</identifier><identifier>PMID: 39610517</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Care and treatment ; Diabetes ; Diabetes therapy ; Diabetics ; Drug resistance ; Endocrinology ; Gene expression ; Genes ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Metformin ; Research Article ; Type 2 diabetes</subject><ispartof>Journal of diabetes and metabolic disorders, 2024-07, Vol.23 (2), p.2021-2030</ispartof><rights>The Author(s), under exclusive licence to Tehran University of Medical Sciences 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>COPYRIGHT 2024 BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-9d926aa4f68265ea13bc8da3196e0399b1142c010e70313483f74e5756d90c4c3</cites><orcidid>0000-0003-1767-7475 ; 0000-0001-6031-7278</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40200-024-01458-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40200-024-01458-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39610517$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mansouri, Vahid</creatorcontrib><creatorcontrib>Bandarian, Fatemeh</creatorcontrib><creatorcontrib>Razi, Farideh</creatorcontrib><creatorcontrib>Razzaghi, Zahra</creatorcontrib><creatorcontrib>Rezaei-Tavirani, Majid</creatorcontrib><creatorcontrib>Rezaei, Mitra</creatorcontrib><creatorcontrib>Arjmand, Babak</creatorcontrib><creatorcontrib>Rezaei-Tavirani, Mostafa</creatorcontrib><title>NF-kappa B signaling pathway is associated with metformin resistance in type 2 diabetes patients</title><title>Journal of diabetes and metabolic disorders</title><addtitle>J Diabetes Metab Disord</addtitle><addtitle>J Diabetes Metab Disord</addtitle><description>Introduction
Metformin is an essential medicine that is most widely prescribed frontline for the treatment of Type 2 diabetes (T2D). Metformin upgraded glycemic control in T2D patients without hypoglycemic effects in patients. This assessment aims to understand molecular mechanism mechanisms in non-responder patients to metformin.
Methods
Gene expression profiles of responder and non-responder T2D patients to metformin are extracted from Gene Expression Omnibus (GEO) and are evaluated by the GEO2R program to find the significant differentially expressed genes (DEGs). The significant DEGs have been studied via action map gene ontology analyses.
Results
Results indicate that 563 significant DEGs discriminate non-responders from responder groups. “NF-kappa B signaling pathway” and 11 DEGs including BIRC3, CCL4L2, CXCL2, ICAM1, LYN, MYD88, RELA, SYK, TLR4, TNFAIP3, and TRIM25 were pointed out as core of drug resistance.
Conclusion
It can be concluded that there are differences between gene expression analysis, the response of diabetic patients to metformin. Results indicate that dysregulation of the “NF-kappa B signaling pathway” and TNFAIP3, BIRC3, RELA, MYD88, TLR4, and ICAM1 is associated with drug resistance in T2D patients.</description><subject>Care and treatment</subject><subject>Diabetes</subject><subject>Diabetes therapy</subject><subject>Diabetics</subject><subject>Drug resistance</subject><subject>Endocrinology</subject><subject>Gene expression</subject><subject>Genes</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Metformin</subject><subject>Research Article</subject><subject>Type 2 diabetes</subject><issn>2251-6581</issn><issn>2251-6581</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kU1rFTEUhoMottT-ARcSEMTN1HzMZDLLWlorFN3oOuZmztybOpOMORnK_ffmOrW0ICaLfD3vC-Eh5DVnZ5yx9gPWTDBWMVFXjNeNrvQzcixEwyvVaP780f6InCLesjLaVmuuXpIj2SnOGt4ekx9frqqfdp4t_UjRb4MdfdjS2ebdnd1Tj9QiRudthp7e-byjE-QhpskHmgA9Zhsc0HLK-xmooL23G8iAhwoPIeMr8mKwI8Lp_XpCvl9dfru4rm6-fvp8cX5TOSlUrrq-E8raelBaqAYslxuneyt5p4DJrttwXgvHOIOWSS5rLYe2hqZtVN8xVzt5Qt6vvXOKvxbAbCaPDsbRBogLmkOIKa21LOjbFd3aEYwPQ8zJugNuzjVjUvLCFursH1SZPUzexQCDL_dPAu8eBXZgx7zDOC7Zx4BPQbGCLkXEBIOZk59s2hvOzEGuWeWaItf8kWt0Cb25_9-ymaB_iPxVWQC5AliewhaSuY1LKkLxf7W_AZyaq5c</recordid><startdate>20240706</startdate><enddate>20240706</enddate><creator>Mansouri, Vahid</creator><creator>Bandarian, Fatemeh</creator><creator>Razi, Farideh</creator><creator>Razzaghi, Zahra</creator><creator>Rezaei-Tavirani, Majid</creator><creator>Rezaei, Mitra</creator><creator>Arjmand, Babak</creator><creator>Rezaei-Tavirani, Mostafa</creator><general>Springer International Publishing</general><general>BioMed Central Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1767-7475</orcidid><orcidid>https://orcid.org/0000-0001-6031-7278</orcidid></search><sort><creationdate>20240706</creationdate><title>NF-kappa B signaling pathway is associated with metformin resistance in type 2 diabetes patients</title><author>Mansouri, Vahid ; Bandarian, Fatemeh ; Razi, Farideh ; Razzaghi, Zahra ; Rezaei-Tavirani, Majid ; Rezaei, Mitra ; Arjmand, Babak ; Rezaei-Tavirani, Mostafa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-9d926aa4f68265ea13bc8da3196e0399b1142c010e70313483f74e5756d90c4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Care and treatment</topic><topic>Diabetes</topic><topic>Diabetes therapy</topic><topic>Diabetics</topic><topic>Drug resistance</topic><topic>Endocrinology</topic><topic>Gene expression</topic><topic>Genes</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Metformin</topic><topic>Research Article</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mansouri, Vahid</creatorcontrib><creatorcontrib>Bandarian, Fatemeh</creatorcontrib><creatorcontrib>Razi, Farideh</creatorcontrib><creatorcontrib>Razzaghi, Zahra</creatorcontrib><creatorcontrib>Rezaei-Tavirani, Majid</creatorcontrib><creatorcontrib>Rezaei, Mitra</creatorcontrib><creatorcontrib>Arjmand, Babak</creatorcontrib><creatorcontrib>Rezaei-Tavirani, Mostafa</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of diabetes and metabolic disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mansouri, Vahid</au><au>Bandarian, Fatemeh</au><au>Razi, Farideh</au><au>Razzaghi, Zahra</au><au>Rezaei-Tavirani, Majid</au><au>Rezaei, Mitra</au><au>Arjmand, Babak</au><au>Rezaei-Tavirani, Mostafa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NF-kappa B signaling pathway is associated with metformin resistance in type 2 diabetes patients</atitle><jtitle>Journal of diabetes and metabolic disorders</jtitle><stitle>J Diabetes Metab Disord</stitle><addtitle>J Diabetes Metab Disord</addtitle><date>2024-07-06</date><risdate>2024</risdate><volume>23</volume><issue>2</issue><spage>2021</spage><epage>2030</epage><pages>2021-2030</pages><issn>2251-6581</issn><eissn>2251-6581</eissn><abstract>Introduction
Metformin is an essential medicine that is most widely prescribed frontline for the treatment of Type 2 diabetes (T2D). Metformin upgraded glycemic control in T2D patients without hypoglycemic effects in patients. This assessment aims to understand molecular mechanism mechanisms in non-responder patients to metformin.
Methods
Gene expression profiles of responder and non-responder T2D patients to metformin are extracted from Gene Expression Omnibus (GEO) and are evaluated by the GEO2R program to find the significant differentially expressed genes (DEGs). The significant DEGs have been studied via action map gene ontology analyses.
Results
Results indicate that 563 significant DEGs discriminate non-responders from responder groups. “NF-kappa B signaling pathway” and 11 DEGs including BIRC3, CCL4L2, CXCL2, ICAM1, LYN, MYD88, RELA, SYK, TLR4, TNFAIP3, and TRIM25 were pointed out as core of drug resistance.
Conclusion
It can be concluded that there are differences between gene expression analysis, the response of diabetic patients to metformin. Results indicate that dysregulation of the “NF-kappa B signaling pathway” and TNFAIP3, BIRC3, RELA, MYD88, TLR4, and ICAM1 is associated with drug resistance in T2D patients.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>39610517</pmid><doi>10.1007/s40200-024-01458-8</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-1767-7475</orcidid><orcidid>https://orcid.org/0000-0001-6031-7278</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2251-6581 |
| ispartof | Journal of diabetes and metabolic disorders, 2024-07, Vol.23 (2), p.2021-2030 |
| issn | 2251-6581 2251-6581 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3134068883 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Care and treatment Diabetes Diabetes therapy Diabetics Drug resistance Endocrinology Gene expression Genes Medicine Medicine & Public Health Metabolic Diseases Metformin Research Article Type 2 diabetes |
| title | NF-kappa B signaling pathway is associated with metformin resistance in type 2 diabetes patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T19%3A12%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NF-kappa%20B%20signaling%20pathway%20is%20associated%20with%20metformin%20resistance%20in%20type%202%20diabetes%20patients&rft.jtitle=Journal%20of%20diabetes%20and%20metabolic%20disorders&rft.au=Mansouri,%20Vahid&rft.date=2024-07-06&rft.volume=23&rft.issue=2&rft.spage=2021&rft.epage=2030&rft.pages=2021-2030&rft.issn=2251-6581&rft.eissn=2251-6581&rft_id=info:doi/10.1007/s40200-024-01458-8&rft_dat=%3Cgale_proqu%3EA800331134%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3134068883&rft_id=info:pmid/39610517&rft_galeid=A800331134&rfr_iscdi=true |